8 unknown, 1 completed, 1 recruiting. 4 Phase 2, 2 Phase 1, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 3, Completed 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Not applicable | 1 | Unknown 1 |
Follow Shen Lin: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mts105 for Advanced Hepatocellular Carcinoma MTS105 - Liver Cancer, Adult, Metastatic Liver Cancers | Phase 1 | Recruiting | Shen Lin | 14 | 2024-11-18 | 2024-12-24 |
| Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy Disitamab Vedotin - HER2, Advanced Gastric Cancer | Unknown | Shen Lin | 306 | 2023-01-01 | 2022-12-16 | |
| A Study of RD14-01 in Patients With Advanced Solid Tumors RD14-01 Cell injection - Solid Tumor | Early Phase 1 | Unknown | Shen Lin | 24 | 2022-12-01 | 2022-12-06 |
| Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer neoantigen tumor vaccine with or without PD-1/L1 - Gastric Cancer | Not applicable | Unknown | Shen Lin | 36 | 2022-03-01 | 2022-02-07 |
| An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors No interventions - To Evaluate the Safety and Effectiveness of Immunotherapy During the Perioperative Treatment Stage in MSI-H Gastrointestinal Cancer | Unknown | Shen Lin | 100 | 2021-01-01 | 2020-12-01 | |
| Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy EV-array - Advanced Gastric Adenocarcinoma, Immunotherapy | Unknown | Shen Lin | 40 | 2018-11-01 | 2021-08-06 | |
| Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System chemotherapy in combination with trastuzumab for arm1, chemotherapy in combination with trastuzumab for arm2, chemotherapy in combination with trastuzumab for arm3 - Targeted Therapy, HER2 | Phase 2 | Unknown | Shen Lin | 100 | 2017-07-01 | 2019-07-19 |
| Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy - Esophageal Squamous Cell Cancer | Phase 2 | Unknown | Shen Lin | 70 | 2013-12-01 | 2013-12-19 |
| Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy - Esophageal Squamous Cell Cancer, Elderly Patients | Phase 2 | Unknown | Shen Lin | 50 | 2013-12-01 | 2013-12-19 |
| Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China S-1, leucovorin, oxaliplatin - Colorectal Cancer | Phase 1 / Phase 2 | Completed | Shen Lin | 20 | 2009-09-01 | 2015-05-19 |
Esophageal Squamous Cell Carcinoma (3) · Colorectal Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma, Hepatocellular (1) · Liver Neoplasms (1) · Stomach Neoplasms (1)
Radiotherapy (2) · 26S proteasome non-ATPase regulatory subunit 13 (1) · Cisplatin (1) · Drug Therapy (1) · JPT1 protein, human (1) · Leucovorin (1) · Long-Term Synaptic Depression (1) · Oxaliplatin (1) · Paclitaxel (1) · S 1 (combination) (1) · Trastuzumab (1) · disitamab vedotin (1)
China (9)
Lin Shen, MD (3) · Lin Shen, Master (1) · Lin Shen, Prof. Dr. (1)